Hiring your first Japan-based regulatory affairs director should take weeks, not the 12 to 18 months it takes to set up a pharmaceutical entity and work through the licensing prerequisites that come with it. For life sciences companies entering Japan, whether to support a clinical program, prepare a PMDA submission, or build early commercial coverage, the operational need for Japan-based talent arrives well before a Japan legal entity is commercially justified. An Employer of Record (EOR) structure closes that gap: a Japan-established entity becomes the legal employer, the foreign company directs the work, and the hire is on-ground and compliant from day one.
Why Life Sciences Companies Need Japan Staff Before They Have a Japan Entity
The Japan life sciences market has a distinctive onboarding sequence. Regulatory approval, clinical operations, and commercial launch are sequential in ways that make early headcount essential but early entity setup premature.
A regulatory affairs specialist needs to be in market to manage Pharmaceuticals and Medical Devices Agency (PMDA) pre-consultation meetings, prepare Japanese-language dossiers, and coordinate with the local marketing authorization (製造販売承認) process. That work typically begins two to four years before a product generates Japan revenue. Similarly, clinical research associates (CRAs) are required on-site at investigator sites during trial conduct, often before the sponsor has any Japan corporate infrastructure. Medical science liaisons (MSLs) covering key opinion leaders in oncology, rare disease, or CNS need to be embedded in the medical community before launch, not after approval.
Market access managers, pharmacovigilance staff, and health economics leads face the same timing constraint. The regulatory and commercial groundwork that determines whether a product succeeds in Japan is done by people in Japan, and it is done well before the revenue profile justifies the cost and complexity of a Japan subsidiary, annual tax filing obligations, representative director appointment, and the capital requirements that come with a properly capitalised entity.
An EOR allows a foreign life sciences company to place one, two, or five people in Japan on compliant employment contracts, under Japanese labor law, with full social insurance coverage, without any of that entity infrastructure.
What EOR Provides in the Life Sciences Context
Under an EOR arrangement, the EOR provider becomes the legal employer of record in Japan. The foreign company retains full operational control: it sets the role, directs the work, and manages performance. The EOR handles the legal and administrative employer obligations.
In practical terms, that means:
(a) Employment contract drafted and executed under Japanese law, including mandatory provisions required by the Labor Standards Act (労働基準法).
(b) Payroll and withholding, including income tax withholding and remittance to the relevant tax authorities on the statutory schedule.
(c) Social insurance (社会保険) enrollment and monthly contributions across all four mandatory programs: health insurance (健康保険) under the Health Insurance Act (健康保険法), employees' pension insurance (厚生年金) under the Employees' Pension Insurance Act (厚生年金保険法), employment insurance (雇用保険) under the Employment Insurance Act (雇用保険法), and workers' accident compensation insurance (労働者災害補償保険).
(d) Work visa (就労ビザ) sponsorship and management. The EOR, as the legal employer with a Japan address and active payroll, is the entity that sponsors the visa. For most life sciences professionals, the applicable category is the Engineer/Specialist in Humanities/International Services visa (技術・人文知識・国際業務ビザ). The EOR files the certificate of eligibility application, manages renewals, and handles the administrative relationship with the Immigration Services Agency (出入国在留管理庁).
(e) Ongoing labor law compliance: maintenance of work rules (就業規則), handling of statutory leave entitlements, and management of any employment changes within the requirements of Japanese law.
The foreign company pays a consolidated fee to the EOR covering the employee's salary, all statutory costs, and the EOR provider's service fee. There is no need for a Japan corporate bank account, payroll system, or social insurance registration in the foreign company's own name.
Life Sciences-Specific Hiring Considerations
MSL and Medical Representative Roles
Medical science liaisons are not regulated as a professional license category in Japan, but their work involves scientific exchange with physicians and healthcare professionals. EOR is fully appropriate for MSL roles. The hire should be an individual with relevant therapeutic area expertise, and the foreign company should ensure the scope of activity does not drift into promotional activity regulated under the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (医薬品、医療機器等の品質、有効性及び安全性の確保等に関する法律), commonly referred to as the PMD Act. Educational and scientific exchange is within scope for an MSL on EOR. Promotional detailing in connection with a product that does not yet have Japan marketing approval is a separate regulatory question.
Medical representatives (MRs) in the traditional sense operate in connection with approved marketed products. If the foreign company's product is not yet approved in Japan, MR-style commercial activity is not available regardless of employment structure.
Regulatory Affairs Specialists and PMDA Liaisons
Regulatory affairs professionals are among the most common early hires for foreign pharma and biotech under EOR. There are no licensing requirements for regulatory affairs staff as such. However, the statutory marketing authorization holder (製造販売業者) for a Japan product approval must itself hold a Marketing Authorization Holder (MAH) license (製造販売業許可). An EOR-employed regulatory affairs director can prepare submissions, manage agency interactions, and coordinate clinical data packages, but the company seeking approval must hold or be partnered with an entity holding the relevant MAH license. EOR covers the employment; it does not substitute for the MAH licensing obligation of the approval applicant.
This is not a limitation of EOR specifically. It is the baseline Japan regulatory requirement. Many foreign companies at the pre-approval stage work through a contract MAH or a Japan distribution partner who holds the license, while the foreign company's own Japan-based regulatory affairs team on EOR manages the scientific and technical work.
Clinical Research Staff
CRAs, clinical trial monitors, and clinical operations managers are standard EOR hires in the life sciences sector. Japan-based CRAs need to operate under the Good Clinical Practice (GCP) standards applicable to the trial type. Employment under EOR does not affect GCP compliance obligations, which attach to the sponsor and the investigational site, not to the employment structure of the monitor.
For clinical trials conducted in Japan, the sponsor of record should verify that having clinical operations staff employed through an EOR rather than a Japan sponsor subsidiary does not create any gap in the contractual chain required by GCP. In practice, most contract research organization and sponsor arrangements accommodate EOR-employed staff through appropriate clinical trial agreements.
Roles Requiring Japanese Professional Licenses
This is the most important limitation of EOR for life sciences companies, and one that is sometimes overlooked.
Certain roles in the life sciences sector require the individual to hold a Japanese professional license to perform the regulated activity. The most common examples:
(a) Physician (医師): licensed under the Medical Practitioners Act (医師法). Active clinical practice, medical diagnosis, and prescription require a Japanese medical license regardless of employment structure.
(b) Pharmacist (薬剤師): licensed under the Pharmacists Act (薬剤師法). Dispensing, supervising pharmaceutical manufacturing quality, and holding the role of General Manager (総括製造販売責任者) in certain MAH structures require a Japan pharmacist license.
(c) Registered nurse and other allied health professionals: subject to their own licensing acts.
EOR does not affect licensing. An EOR-employed pharmacist who holds a valid Japanese pharmacy license can perform regulated pharmacist activities. An individual without the Japanese license cannot perform those activities regardless of how they are employed. When a foreign life sciences company needs to fill a role that requires a Japanese professional license, the first question is whether the candidate already holds that license. If they do, EOR is a viable employment structure. If the role requires functions that can only be performed by a licensed individual and the candidate does not hold the Japanese license, EOR will not resolve that regulatory gap.
Pharmaceutical quality persons and pharmacovigilance physicians similarly need to satisfy the substantive professional requirements of their roles under Japanese regulation, separate from how their employment is structured.
Employment Contract Structure Under Japanese Law
Every employee hired through EOR in Japan is employed under a contract that must comply with the Labor Standards Act (労働基準法). Several provisions are mandatory and cannot be contracted around.
Trial period (試用期間): A probationary period is standard and legally permissible in Japan, typically ranging from three to six months. During the trial period, the threshold for dismissal is somewhat lower than after regularisation, but termination still requires objective and reasonable grounds. The right to terminate at-will during a trial period does not exist under Japanese law.
Termination rules: Japan has strong employment protections. The Labor Standards Act requires 30 days' advance notice before dismissal, or payment in lieu. Beyond notice, the doctrine of abusive dismissal (解雇権濫用法理), now codified in the Labor Contract Act (労働契約法), means that a dismissal lacking objectively reasonable grounds and social acceptability will be found invalid by Japanese courts. Redundancy terminations require additional procedural steps: genuine business necessity, exploration of alternatives to dismissal, fair employee selection criteria, and consultation. For foreign companies used to at-will employment in the US or notice-only termination in parts of the EU, the Japan standard is meaningfully more restrictive. The EOR provider manages compliance with these rules, but the foreign company should understand them before making headcount commitments.
Working hours: The Labor Standards Act sets a statutory maximum of 8 hours per day and 40 hours per week. Overtime requires a 36 Agreement (三六協定) filed with the local Labour Standards Inspection Office (労働基準監督署). The EOR maintains these filings.
Annual paid leave (年次有給休暇): Employees accrue paid leave entitlements from the date of hire, with the first 10 days vesting after six months of continuous employment. These entitlements are statutory and cannot be waived.
The Transition Point: From EOR to Japan Entity
EOR is a practical market entry tool, not a permanent operating structure for a mature Japan operation. There are several indicators that a foreign life sciences company should consider transitioning to a Japan legal entity.
Headcount and operational scale: When the Japan team grows to five or more people and is conducting ongoing commercial or operational activity, the management overhead of EOR relative to operating a Japan entity begins to narrow. A Japan Godo Kaisha (合同会社, GK) or Kabushiki Kaisha (株式会社, KK) can be incorporated within a few weeks once the decision is made.
Revenue and tax considerations: If the Japan operation is generating billable revenue, contracting directly with Japan customers, or managing significant local expenses, the foreign company may be creating a permanent establishment (恒久的施設) exposure regardless of EOR structure. A qualified tax advisor should assess the permanent establishment question as the Japan operation matures.
PMDA product approval requirements: This is the most Japan-specific trigger for life sciences companies. Certain PMDA approval structures require the applicant to hold a Japan MAH license. The MAH license requires a Japan legal entity. A foreign company pursuing independent Japan approval, rather than using a Japan distribution partner as MAH, will need to incorporate a Japan entity and obtain the relevant license well before the approval application is filed. Planning this transition against the clinical and regulatory timeline is important: MAH license acquisition typically takes six to twelve months and must precede the marketing authorization application.
Substance requirements: Some regulatory frameworks, contract structures, and banking relationships in Japan require a Japan-resident legal entity as a party. As the Japan engagement deepens, the number of situations where the foreign company needs its own Japan entity increases.
The EOR-to-entity transition does not require terminating existing employees. Employment transfers in connection with a corporate restructuring are manageable under Japanese labor law, typically structured as agreed transfers with employee consent. The mechanics require careful planning and should be addressed by the EOR provider and a Japan labor counsel well before the entity formation date.
Common Pitfalls for Pharma and Biotech Companies
Assuming EOR covers all roles in a pharmaceutical operation: EOR is an employment structure. It does not confer the regulatory authorizations, licenses, or organizational standing required by the PMD Act framework. A foreign company sometimes approaches EOR with the expectation that hiring a Japan-based regulatory team through EOR will allow it to conduct all the activities of a Japan MAH. It will not. The MAH license and the Japan legal entity requirements are separate from employment structure.
Overstating visa eligibility for highly specialized clinical roles: Most life sciences professional roles qualify for the Engineer/Specialist in Humanities/International Services visa (技術・人文知識・国際業務). However, the visa requires that the role matches the individual's academic background or professional experience in a recognised category. For highly specialized roles such as medical physicists, certain bioinformatics specialists, or hybrid clinical/regulatory functions, visa eligibility should be confirmed at the scoping stage rather than assumed.
Not accounting for the Japanese licensed pharmacist requirement: A foreign company building a Japan regulatory team will often need a pharmacist or pharmaceutical scientist in a quality or regulatory function. If the role requires activities reserved for licensed pharmacists under Japanese law, the candidate must hold a Japanese license. Confirming this at the job design stage avoids discovering the constraint after an offer has been extended.
Treating the trial period as an at-will period: Foreign companies unfamiliar with Japan labor law sometimes assume that the trial period (試用期間) functions like US at-will employment. It does not. Termination during a trial period requires grounds, and an ill-founded termination during probation carries the same legal risk as one after regularisation. EOR providers manage this, but the foreign company making the hire decision should understand the commitment it is entering.
Delaying the entity timeline for PMDA purposes: Companies that plan to seek Japan approval as the MAH should begin the Japan entity and MAH license process earlier than they expect to need it. Treating EOR as a bridge that removes urgency from entity planning sometimes results in the entity formation timeline colliding with the regulatory submission timeline.
This article is informational only and does not constitute legal, tax, or regulatory advice. Consult a qualified advisor before acting on the content. Last updated: June 2026.